Compare Southern Copper Corp (SCCO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southern Copper Corp vs Viatris Inc — how do they compare? Southern Copper Corp trades at $207.19 (market cap $167.74B), while Viatris Inc trades at $17.58 (market cap $20.03B). The key difference: Southern Copper Corp is far larger — about 8.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Southern Copper Corp for 61 Days and Viatris Inc for 57 Days on average.
| SCCO | VTRS | |
|---|---|---|
Market Cap | $167.74B | $20.03B |
Volume | 853,110 | 14,109,977 |
Sector | Basic Materials | Health |
52-Week High | $219.70 | $18.27 |
52-Week Low | $120.02 | $9.74 |
Typical Hold Time | 61 Days | 57 Days |
Enterprise Value | $169.03B | $32.15B |
Dividend Yield | 2.21% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southern Copper (SCCO) trades at $200.57, down 1.81% on the day, with technical indicators showing a neutral bias. The company demonstrates strong fundamentals with revenue growth from $13.42B in 2025 to projected $15.8B in 2026 and net income margins expanding to 35.87%. Recent earnings have consistently beaten expectations, and the company maintains robust profitability metrics including 50.07% ROE. A stock split and dividend payment are scheduled for August 2026.
SCCO presents a mixed investment case with strong operational performance offset by premium valuations. The stock trades above analyst consensus target of $167.67, suggesting limited near-term upside. Key risks include copper price volatility and competitive pressures, while growth catalysts include Mexican project pipeline development. Analyst sentiment remains divided with only 10.34% buy ratings.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
